Last update : 07/22/2015 | Version : 2 | ID : 74
General | |
Identification | |
Detailed name | First-line treatment of non-small cell lung cancer under routine conditions: observational study on overall survival |
Sign or acronym | FRAME |
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation | CNIL N°909066 |
General Aspects | |
Medical area |
Cancer research Pneumology |
Keywords | Non-small cell lung cancer, first-line chemotherapy, platinum salt, survival, pemetrexed |
Scientific investigator(s) (Contact) | |
Name of the director | Médecin pharmacoépidémiologiste |
fr_mail_pharmacoepi@lilly.com | |
Unit | Eli Lilly France |
Collaborations | |
Funding | |
Funding status |
Private |
Details | Eli Lilly and Company |
Governance of the database | |
Sponsor(s) or organisation(s) responsible | Eli Lilly |
Organisation status |
Private |
Additional contact | |
Main features | |
Type of database | |
Type of database |
Study databases |
Study databases (details) |
Longitudinal study (except cohorts) |
Database recruitment is carried out by an intermediary |
A selection of health institutions and services |
Database recruitment is carried out as part of an interventional study |
No |
Additional information regarding sample selection. | Patients recruited by practitioners. Oncologists and pneumologists caring for patients suffering from non-small cell lung cancer. Random selection of practitioners using a professional file. |
Database objective | |
Main objective |
Primary objective: evaluate the overall survival of patients with a diagnosis of locally advanced or metastatic non-small cell lung cancer (stage IIIb or IV) initiating first-line chemotherapy combined with a platinum salt, whether or not combined with a targeted agent, in a daily practice setting.
Secondary objectives: - Survival at 1 year, survival without progression and tumor response: according to histological subgroup and whether or not a target edagent is used; - Diagnosis of histopathological/cytopathological subtype; - Care pathway and use of resources. |
Inclusion criteria |
Have a histopathological or cytopathological diagnosis of locally advanced or metastatic non-small cell lung cancer (stage IIIb or IV).
- Initiate first-line chemotherapy for a non-small cell lung cancer combined with a platinum salt, whether or not combined with a targeted agent. |
Population type | |
Age |
Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more) |
Population covered |
Sick population |
Gender |
Male Woman |
Geography area |
International |
Detail of the geography area | Europe |
Data collection | |
Dates | |
Date of first collection (YYYY or MM/YYYY) | 2009 |
Date of last collection (YYYY or MM/YYYY) | 2012 |
Size of the database | |
Size of the database (number of individuals) |
[1000-10 000[ individuals |
Details of the number of individuals | 5667 |
Data | |
Database activity |
Current data collection |
Type of data collected |
Clinical data Biological data |
Clinical data (detail) |
Direct physical measures Medical registration |
Biological data (detail) | histology, cytomarkers |
Presence of a biobank |
No |
Health parameters studied |
Health event/morbidity Health event/mortality Health care consumption and services |
Care consumption (detail) |
Hospitalization Medical/paramedical consultation Medicines consumption |
Procedures | |
Data collection method | Study data collection form |
Participant monitoring |
Yes |
Details on monitoring of participants | 18 months follow up |
Links to administrative sources |
No |
Promotion and access | |
Promotion | |
Link to the document | http://tinyurl.com/Pubmed-FRAME |
Description | List of publications in Pubmed |
Access | |
Terms of data access (charter for data provision, format of data, availability delay) | Report and publication |
Access to aggregated data |
Access on specific project only |
Access to individual data |
Access on specific project only |
Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05